Bloomberg reported that Teva Pharmaceutical Industries Ltd. will likely increase its bid for rival Mylan NV by as much as $2 billion, to $43 billion, and may announce the new proposal as soon as this week.
Teva may offer $86 to $88 a share for Mylan, said unnamed sources. That compares with the $82 a share Teva offered in April, a price that valued the Canonsburg, Pennsylvania-based company at about $40.1 billion, the article said. Mylan had a market value of about $34.4 billion as of last week’s close.
Read the full story